Who are Oral IR-LD/CD's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): sinemet plus, carbidopa-levodopa (Sinemet), CLE, IR CD-LD, IPX066.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oral-ir-ld-cd.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Oral IR-LD/CD — Competitive Intelligence Brief

Oral IR-LD/CD (Oral IR-LD/CD) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine replacement therapy. Area: Neurology.

phase 3 Dopamine replacement therapy Dopamine pathway; aromatic amino acid decarboxylase inhibition Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Oral IR-LD/CD (Oral IR-LD/CD) — NeuroDerm Ltd.. Oral IR-LD/CD is a levodopa/carbidopa combination that increases dopamine levels in the brain by delivering levodopa with carbidopa, a decarboxylase inhibitor, to treat motor symptoms of Parkinson's disease.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Oral IR-LD/CD TARGET	Oral IR-LD/CD	NeuroDerm Ltd.	phase 3	Dopamine replacement therapy	Dopamine pathway; aromatic amino acid decarboxylase inhibition
sinemet plus	sinemet plus	Hospital de Granollers	marketed	Dopamine replacement therapy with COMT inhibitor	Dopamine pathway; COMT enzyme
carbidopa-levodopa (Sinemet)	carbidopa-levodopa (Sinemet)	Baylor College of Medicine	marketed	Dopamine replacement therapy	Aromatic amino acid decarboxylase (AADC); dopamine pathway
CLE	CLE	Impax Laboratories, LLC	marketed	Dopamine replacement therapy / Levodopa combination	Dopamine pathway; decarboxylase inhibition
IR CD-LD	IR CD-LD	Impax Laboratories, LLC	phase 3	Dopamine replacement therapy / Decarboxylase inhibitor combination	Dopamine pathway; carbidopa inhibits aromatic L-amino acid decarboxylase
IPX066	IPX066	Impax Laboratories, LLC	phase 3	Dopamine replacement therapy; extended-release levodopa/carbidopa combination	Dopamine pathway (via levodopa conversion to dopamine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine replacement therapy class)

Baylor College of Medicine · 1 drug in this class
NeuroDerm Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oral IR-LD/CD — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-ir-ld-cd. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab